Inovio Pharmaceuticals Inc (INO) - Total Liabilities
Based on the latest financial reports, Inovio Pharmaceuticals Inc (INO) has total liabilities worth $77.11 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Inovio Pharmaceuticals Inc to track the company's year-over-year net asset growth rate.
Inovio Pharmaceuticals Inc - Total Liabilities Trend (1998–2024)
This chart illustrates how Inovio Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See INO free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Inovio Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Inovio Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Airmate Cayman International Co Ltd
TW:1626
|
Taiwan | NT$5.39 Billion |
|
Seres Therapeutics Inc
NASDAQ:MCRB
|
USA | $91.12 Million |
|
Space Hellas SA
AT:SPACE
|
Greece | €158.35 Million |
|
DSR Corp
KO:155660
|
Korea | ₩151.69 Billion |
|
JR HOLDING SA BC ZY -10
F:8JA
|
Germany | €51.60 Million |
|
Hoang Quan Consulting Trading Service Real Estate Corp
VN:HQC
|
Vietnam | ₫3.51 Trillion |
|
Pharmx Technologies Ltd
AU:PHX
|
Australia | AU$2.90 Million |
Liability Composition Analysis (1998–2024)
This chart breaks down Inovio Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Inovio Pharmaceuticals Inc (INO) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -9.99 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Inovio Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Inovio Pharmaceuticals Inc (1998–2024)
The table below shows the annual total liabilities of Inovio Pharmaceuticals Inc from 1998 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $44.69 Million | -16.62% |
| 2023-12-31 | $53.60 Million | -57.52% |
| 2022-12-31 | $126.17 Million | +31.06% |
| 2021-12-31 | $96.27 Million | +22.43% |
| 2020-12-31 | $78.63 Million | -43.25% |
| 2019-12-31 | $138.55 Million | +214.30% |
| 2018-12-31 | $44.08 Million | -1.50% |
| 2017-12-31 | $44.75 Million | -11.08% |
| 2016-12-31 | $50.33 Million | +32.77% |
| 2015-12-31 | $37.91 Million | +87.22% |
| 2014-12-31 | $20.25 Million | -42.78% |
| 2013-12-31 | $35.38 Million | +244.16% |
| 2012-12-31 | $10.28 Million | -22.38% |
| 2011-12-31 | $13.24 Million | +47.72% |
| 2010-12-31 | $8.97 Million | -53.89% |
| 2009-12-31 | $19.44 Million | -2.20% |
| 2008-12-31 | $19.88 Million | +127.46% |
| 2007-12-31 | $8.74 Million | -29.78% |
| 2006-12-31 | $12.45 Million | +125.99% |
| 2005-12-31 | $5.51 Million | +1.97% |
| 2004-12-31 | $5.40 Million | +357.27% |
| 2003-12-31 | $1.18 Million | -30.26% |
| 2002-12-31 | $1.69 Million | +1.39% |
| 2001-12-31 | $1.67 Million | +4.68% |
| 2000-12-31 | $1.60 Million | -26.83% |
| 1999-12-31 | $2.18 Million | +45.41% |
| 1998-12-31 | $1.50 Million | -- |
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA s… Read more